split-banner-image

APHINITY

Closed

ANZ 1102/BIG 4-11/BO25126/TOC4939G: APHINITY

BCT Study Chair:

Nicholas Wilcken

This trial seeks to evaluate the efficacy and safety of a new drug, called pertuzumab, in the treatment of patients with HER2-positive breast cancer. It is thought that this new drug may further improve long term survival for women and men diagnosed with this type of breast cancer. APHINITY will compare treatment with the current standard of care, trastuzumab, to treatment with both trastuzumab and pertuzumab.

international

4677

INTERNATIONAL

Total number of trial

participants internationally

australia & new zealand

128

AUSTRALIA & NEW ZEALAND

Total number of trial participants

in Australia and New Zealand

institutions

15

INSTITUTIONS

Total number of participating institutions

in Australia and New Zealand

APHINITY PUBLICATIONS

2024

Adjuvant Pertuzumab and Trastuzumab in Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer in the APHINITY Trial: Third Interim Overall Survival Analysis With Efficacy Update.

Loibl S, Jassem J, Sonnenblick A, Parlier D, Winer E, Bergh J, Gelber RD, Restuccia E, Im Y-H, Huang C-S, Dalenc F, Clavo I, Procter M, Caballero C, Clark E, Raimbault A, McConnell, Monturus E, de Azambuja E, Gomez HL, Bliss J, Viale G, Bines J, Piccart M, on behalf of the APHINITY Steering Committee and Investigators. Journal of Clinical Oncology. 2024; 1-14, 0, JCO.23.02505; DOI:10.1200/JCO.23.02505, E-pub

2023

The benefit of adjuvant pertuzumab and trastuzumab according to estrogen receptor and HER2 expression: sub-analysis of the APHINITY trial.

de Azambuja E, Agostinetto E, Samy F, Di Cosimo S, Aftimos P, Ponde N, Eiger D, Lambertini M, Cameron D, Kiermaier A, Bailey A, Viale G, Loi S, Piccart M. SABCS 2023; PS09-04, Abstract

2022

Residual Risk of Relapse: a Systematic Review and a Consensus Project on Unmet needs for HER2-positive non Metastatic Breast Cancer Patients.

Miglietta F, Pronzato P, Girardi F, Griguolo G, Guarneri V, Pappagallo G, Conte P, Periplo foundation. European Journal of Cancer. 2022; 175(S1):s57-S58, EBCC-13 Abstract 177/PB-090, Poster

Adjuvant pertuzumab and trastuzumab in patients with early HER-2 positive breast cancer in APHINITY: 8.4 years' follow up.

Loibl S, Jassem J, Sonnenblick A, Parlier D, Winer E, Bergh J, Gelber RD, Restuccia E, Im Y-H, Huang C, Dalenc F, Calvo I, Procter M, Caballero C, Clark E, Gomez Moreno HL, Bliss J, Viale G, Bines J, Piccart M. Annals of Oncology. 2022; 33(9):986-987 , VPS-2022 (ESMO 2022), Abstract

Impact of Age on Clinical Outcomes and Efficacy of Adjuvant Dual Anti-HER2 Targeted Therapy.

Lambertini M, Fielding S, Loibl S, Janni W, Clark E, Franzoi MA, Fumagalli D, Caballero C, Arecco L, Salomoni S, Ponde NF, Poggio F, Kim HJ, Villarreal-Garza C, Pagani O, Paluch-Shimon S, Ballestrero A, Del Mastro L, Piccart M, Bines J, Partridge AH, de Azambuja E. Journal of the National Cancer Institute. 2022; (00)(epub 5 May 2022), E-pub

Timelines to initiate a phase III trial across the globe: a sub-analysis of the APHINITY trial.

Franzoi MA, Procter M, Twelves C, Ponde N, Eiger D, Emond O, Clark E, Parlier D, Guillaume S, Reaby L, de Azambuja E and Bines J. ecancermedicalscience. 2022; 16(1379): Journal

LOAD MORE

Institutions